Fmr LLC Has $163.44 Million Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

Fmr LLC increased its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 2.4% during the 4th quarter, HoldingsChannel reports. The firm owned 8,019,746 shares of the company’s stock after purchasing an additional 188,368 shares during the period. Fmr LLC owned about 0.06% of Denali Therapeutics worth $163,442,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. KLP Kapitalforvaltning AS bought a new position in Denali Therapeutics in the fourth quarter valued at approximately $532,000. Proficio Capital Partners LLC bought a new stake in Denali Therapeutics in the 4th quarter valued at $514,000. JPMorgan Chase & Co. boosted its stake in Denali Therapeutics by 6.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company’s stock worth $6,857,000 after purchasing an additional 14,324 shares during the period. Principal Financial Group Inc. increased its holdings in Denali Therapeutics by 13.8% during the 3rd quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock worth $36,076,000 after purchasing an additional 149,939 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Denali Therapeutics by 7.6% in the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company’s stock valued at $244,993,000 after purchasing an additional 843,996 shares during the period. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on DNLI shares. William Blair reaffirmed an “outperform” rating on shares of Denali Therapeutics in a research report on Friday, February 28th. Baird R W raised Denali Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 7th. Bank of America lowered their price objective on shares of Denali Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, March 10th. JPMorgan Chase & Co. reduced their target price on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a report on Tuesday, January 7th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Denali Therapeutics in a research note on Tuesday, February 11th. They issued a “buy” rating and a $31.00 price target on the stock. One analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $37.57.

Denali Therapeutics Stock Up 1.6 %

Shares of NASDAQ DNLI opened at $12.70 on Friday. The business’s 50 day moving average price is $16.53 and its two-hundred day moving average price is $21.83. The company has a market cap of $1.84 billion, a PE ratio of -4.60 and a beta of 1.58. Denali Therapeutics Inc. has a twelve month low of $10.57 and a twelve month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.08. As a group, research analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.